Earnings Feed
Start Free
Home/Filings/4/0001193125-26-010617
4//SEC Filing

Vida Ventures II, LLC 4

Accession 0001193125-26-010617

CIK 0002035832other
View on SEC.govCompany Profile

Filed

Jan 11, 7:00 PM ET

Accepted

Jan 12, 5:10 PM ET

Size

22.6 KB

Accession

0001193125-26-010617

Insider Transaction Report

Form 4
Period: 2026-01-12
Aktis Oncology, Inc.AKTS
Vida Ventures II, LLC
10% Owner
Transactions
  • Conversion

    Series A Redeemable Convertible Preferred Stock

    [F4][F3]
    2026-01-12−411,750→ 0 total(indirect: See Footnote)
    → Common Stock (108,229 underlying)
  • Conversion

    Common Stock

    [F1][F2]
    2026-01-12+4,859,370→ 4,859,370 total(indirect: See Footnote)
  • Purchase

    Common Stock

    [F2]
    2026-01-12$18.00/sh+812,455$14,624,190→ 5,671,825 total(indirect: See Footnote)
  • Conversion

    Common Stock

    [F1][F3]
    2026-01-12+134,842→ 134,842 total(indirect: See Footnote)
  • Purchase

    Common Stock

    [F3]
    2026-01-12$18.00/sh+22,545$405,810→ 157,387 total(indirect: See Footnote)
  • Conversion

    Series A Redeemable Convertible Preferred Stock

    [F4][F2]
    2026-01-12−14,838,250→ 0 total(indirect: See Footnote)
    → Common Stock (3,900,284 underlying)
  • Conversion

    Series B Redeemable Convertible Preferred Stock

    [F5][F2]
    2026-01-12−3,648,750→ 0 total(indirect: See Footnote)
    → Common Stock (959,086 underlying)
  • Conversion

    Series B Redeemable Convertible Preferred Stock

    [F5][F3]
    2026-01-12−101,250→ 0 total(indirect: See Footnote)
    → Common Stock (26,613 underlying)
VIDA VENTURES II-A, LLC
10% Owner
Transactions
  • Conversion

    Common Stock

    [F1][F2]
    2026-01-12+4,859,370→ 4,859,370 total(indirect: See Footnote)
  • Purchase

    Common Stock

    [F2]
    2026-01-12$18.00/sh+812,455$14,624,190→ 5,671,825 total(indirect: See Footnote)
  • Conversion

    Common Stock

    [F1][F3]
    2026-01-12+134,842→ 134,842 total(indirect: See Footnote)
  • Purchase

    Common Stock

    [F3]
    2026-01-12$18.00/sh+22,545$405,810→ 157,387 total(indirect: See Footnote)
  • Conversion

    Series A Redeemable Convertible Preferred Stock

    [F4][F2]
    2026-01-12−14,838,250→ 0 total(indirect: See Footnote)
    → Common Stock (3,900,284 underlying)
  • Conversion

    Series A Redeemable Convertible Preferred Stock

    [F4][F3]
    2026-01-12−411,750→ 0 total(indirect: See Footnote)
    → Common Stock (108,229 underlying)
  • Conversion

    Series B Redeemable Convertible Preferred Stock

    [F5][F2]
    2026-01-12−3,648,750→ 0 total(indirect: See Footnote)
    → Common Stock (959,086 underlying)
  • Conversion

    Series B Redeemable Convertible Preferred Stock

    [F5][F3]
    2026-01-12−101,250→ 0 total(indirect: See Footnote)
    → Common Stock (26,613 underlying)
Footnotes (5)
  • [F1]Represents shares of the Issuer's Common Stock received upon conversion of shares of the Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock on a 3.8044-for-1 basis without payment of additional consideration.
  • [F2]These shares are held by Vida Ventures II, LLC ("VV II"). VV Manager II, LLC ("VVM II") is the manager of VV II and may be deemed to have voting, investment and dispositive power with respect to the shares held by VV II. Arie Belldegrun, Fred Cohen, and Leonard Potter, the members of the management committee of VVM II, along with the other members of the investment committee of VVM II, Rajul Jain, Joshua Kazam, and Helen Kim, a member of the Issuer's board of directors, may be deemed to share voting, investment and dispositive power over the shares held by VV II and each such person disclaims beneficial ownership of the securities except to the extent of such person's pecuniary interest therein.
  • [F3]These shares are held by Vida Ventures II-A, LLC ("VV II-A"). VVM II is the manager of VV II-A and may be deemed to have voting, investment and dispositive power with respect to the shares held by VV II-A. Arie Belldegrun, Fred Cohen, and Leonard Potter, the members of the management committee of VVM II, along with the other members of the investment committee of VVM II, Rajul Jain, Joshua Kazam, and Helen Kim, a member of the Issuer's board of directors, may be deemed to share voting, investment and dispositive power over the shares held by VV II-A and each such person disclaims beneficial ownership of the securities except to the extent of such person's pecuniary interest therein.
  • [F4]The Series A Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration.
  • [F5]The Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration.

Documents

1 file

Issuer

Aktis Oncology, Inc.

CIK 0002035832

→
Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001776851

Filing Metadata

Form type
4
Filed
Jan 11, 7:00 PM ET
Accepted
Jan 12, 5:10 PM ET
Size
22.6 KB
View on SEC.gov